YOU ARE HERE:
Starting treatment news
page  of 15
 
Headline
Date
  High rate of death amongst patients with HIV diagnosed late
20.11.08
  IL-2 provides quick ‘AIDS rescue’, but effect does not always last
17.11.08
  Treatment breaks set for a come-back?
12.11.08
  Kivexa downgraded to alternative status in revised US HIV treatment guidelines
05.11.08
  Enhanced Trofile assay better at identifying HIV tropisms, only slight impact on virologic outcomes
31.10.08
  Tenofovir/FTC more effective than abacavir/3TC in first-line boosted-PI regimens: meta-analysis
29.10.08
  Start treatment at CD4 cell counts below 500, says large cohort study
27.10.08
  No significant differences between elvucitabine and 3TC at 48 weeks
27.10.08
  Raltegravir non-inferior to efavirenz: 48 week, phase III results
27.10.08
  Once-daily darunavir (Prezista) approved for first-line use in United States
22.10.08
  Is there a role for tropism testing in routine HIV care?
22.10.08
  Low rate of spontaneous hepatitis C clearance in patients with HIV; early HIV treatment recommended for those with chronic hepatitis C infection
02.10.08
  Hypersensitivity testing for abacavir slightly more cost-effective than tenofovir use, if both drugs equally potent
30.09.08
  More evidence that antiretrovirals reduce the risk of non-HIV illnesses at lower CD4 cell counts
23.09.08
  Patients staying on first-line HIV treatment combinations for longer
16.09.08
  Study shows patients in their 30s at time of HIV infection have best response to HIV therapy
10.09.08
  Poor results using non-medical HIV counsellors to screen for treatment eligibility in Malawi
03.09.08
  How does abacavir/3TC compare to tenofovir/FTC? ACTG5202 and GSK studies disagree
08.08.08
  Slowing CD4 cell decline with IL-2 allows HIV treatment to be deferred by 92 weeks
06.08.08
  Efavirenz superior to lopinavir/ritonavir in very advanced HIV, Mexican trial shows
06.08.08

page  of 15